NCT05582161 · Phase 2 · RECRUITING
Efficacy Biomarkers of DAOIB for Dementia
This trial gives an experimental drug called DAOIB to people with amnestic mild cognitive impairment or mild Alzheimer's for 24 weeks. Researchers will track blood markers tied to NMDA signaling and oxidative stress, to see if they predict who responds. Everyone gets the drug. It's a Phase 2 trial, testing whether it works and is safe, not yet proven or approved.
You may qualify if
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- MMSE between 10-26
- CDR 1 or 0.5
You're excluded if
- Hachinski Ischemic Score > 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-19